Join the club for FREE to access the whole archive and other member benefits.

Metformin misinterpreted as antiaging drug via animal studies, TAME heads for future trials

More than 90% of drugs safe and effective when tested in experimental animals fail in human testing

04-Oct-2022

Key points from article :

Metformin has been proposed as an anti-aging drug, but TAME may help pave the way to important future trials of longevity therapeutics.

Fewer chances are that metformin will slow the rate of aging in humans.

The animal (mice and rats) studies got many scientists excited about metformin in the first place but they went wrong.

Hevolution Foundation has agreed to provide the last tranche of funding for the long-delayed Targeting Aging with Metformin (TAME) trial.

TAME is a large-scale human trial to see if the cheap, safe diabetes drug metformin can slow aging in a cohort of several thousand aging but nondiabetic people.

Metformin very slightly increased median survival at a lower dose, but shortened life at the higher dose in mice.

Metformin failed to extend lifespan in the NIA’s Interventions Testing Program (ITP).

The results were published in the Aging cell. 

Mentioned in this article:

Click on resource name for more details.

Aging Cell

Scientific journal devoted to age related diseases

Hevolution Foundation

Non-profit organization that funds research, Riyadh, Saudi Arabia

Topics mentioned on this page:
Metformin
Metformin misinterpreted as antiaging drug via animal studies, TAME heads for future trials